Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
Ryan L. Steinberg(University of Iowa), Michael A. O’Donnell(University of Iowa Health Care), Marcus J. Daniels(Johns Hopkins University), Supriya Nagaraju(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), M. Eric Hyndman(University of Calgary), Sarah L. Mott(University of Iowa Holden Comprehensive Cancer Center), Trafford Crump(University of Calgary), Donald L. Lamm(The University of Texas System), Kenneth G. Nepple(University of Iowa), Mounica Y. Rao(University of Arizona), Nathan A. Brooks(Eli Lilly (United States)), Lewis J. Thomas(Washington University in St. Louis), Trinity J. Bivalacqua(Hospital of the University of Pennsylvania), Jonathan Wang(Beth Israel Deaconess Medical Center), William C. DeWolf(Beth Israel Deaconess Medical Center), Max Kates(Duke Medical Center), Andrew Vitale(University of Iowa)
Cited by 190
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
|Nature Reviews Urology|2022|196
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19
|Nature Reviews Urology|2021|154
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
|Molecular Cancer Therapeutics|2013|121